(VIANEWS) – The Market ended the session with POXEL (POXEL.PA) rising 34.96% to €0.94 on Tuesday while CAC 40 slid 0.46% to €7,339.27.
POXEL’s last close was €0.70, 78.71% below its 52-week high of €3.28.
About POXEL
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). Poxel S.A. has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. The company was incorporated in 2009 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, POXEL has a trailing twelve months EPS of €-1.02.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -323.36%.
Moving Average
POXEL’s value is above its 50-day moving average of €0.91 and way under its 200-day moving average of €1.51.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, POXEL’s stock is considered to be oversold (<=20).
Yearly Top and Bottom Value
POXEL’s stock is valued at €0.94 at 21:40 EST, way under its 52-week high of €3.28 and way above its 52-week low of €0.65.
Volume
Today’s last reported volume for POXEL is 1104540 which is 1485.19% above its average volume of 69679.
More news about POXEL (POXEL.PA).
